Regentis Biomaterials Ltd. (RGNT) stock
Close on Nov 18, 2026Market cap $5.90MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.90M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.77
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$13.65M
- EPS, diluted
- -$24.16
Trading
- Previous close
- $1.22
- Open
- $1.22
- Day's range
- $1.14 – $1.22
- Volume
- 9,157
- Average volume (20 days)
- 46,874
- 52-week range
- $1.14 – $15.50
- RSI (14 days)
- 33.8
- Volatility (1 year)
- 559.3%
- Relative volume
- 0.14×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | RGNT | S&P 500 | Difference | RGNT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.5% | -4.3% | −19.2 pts | ||
| 3 months | -42.7% | -4.6% | −38.1 pts | ||
| Year to date | -83.1% | +7.9% | −91.0 pts | ||
| 1 year | +11300.0% | +11.8% | +11288.2 pts | ||
| 3 years | +11300.0% | +68.0% | +11232.0 pts | +384.9% | +18.9% |
| 5 years | +11300.0% | +66.2% | +11233.8 pts | +157.9% | +10.7% |
| 10 years | +11300.0% | +291.3% | +11008.7 pts | +60.6% | +14.6% |
Four years at a glance
Fiscal years 2022 to 2025, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Regentis Biomaterials filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Regentis Biomaterials
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions designed to restore health and improve patient quality of life. The company focuses on orthopedic therapies utilizing its Gelrin platform, which employs degradable hydrogel implants to regenerate damaged or diseased cartilage. Its primary product candidate is GelrinC, an acellular, off-the-shelf hydrogel cured into an implant to treat painful articular knee cartilage injuries. GelrinC serves human patients suffering from knee cartilage damage and targets European markets through planned partnerships.
Company profile, executives and historyRegentis Biomaterials stock: common questions
What is Regentis Biomaterials's stock price?
RGNT closed at $1.14 on Nov 18, 2026, down 6.56% on the day. Over the past 52 weeks it traded between $1.14 and $15.50.
What is Regentis Biomaterials's market cap?
Regentis Biomaterials was worth $5.90M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is RGNT's P/E ratio?
Regentis Biomaterials lost money over fiscal 2025 (diluted EPS -$24.16), so it has no meaningful P/E ratio.
Does Regentis Biomaterials pay a dividend?
No. Regentis Biomaterials has not paid a cash dividend over the last twelve months.
How has RGNT stock performed over the past year?
Including dividends, RGNT returned +11300.0% over the past year, against +11.8% for the S&P 500.
How many RGNT shares are sold short?
0M shares were sold short at the latest FINRA report, 0.19% of the float, or 1.0 days of average trading volume.
Who are Regentis Biomaterials's competitors?
Companies most similar to Regentis Biomaterials by business, industry and size include OPHI, SNN, ENOV, SMTI, AVR.
See a number that looks wrong?